公开(公告)号：US20100081792A1

公开(公告)日：2010-04-01

申请号：US11981821

申请日：2007-10-31

Applicant: Steven Grant ,  Amrik Basran ,  Olga Ignatovich ,  Rudolph Maria T. De Wildt ,  Philip Jones ,  Neil Brewis ,  Ben Woolven ,  Elena De Angelis ,  Lucy J. Holt ,  Greg Winter ,  Ian Tomlinson ,  Kevin Moulder

Inventor： Steven Grant ,  Amrik Basran ,  Olga Ignatovich ,  Rudolph Maria T. De Wildt ,  Philip Jones ,  Neil Brewis ,  Ben Woolven ,  Elena De Angelis ,  Lucy J. Holt ,  Greg Winter ,  Ian Tomlinson ,  Kevin Moulder

IPC: C07K16/00

CPC classification number: C07K16/468 ,  A61K47/60 ,  A61K2039/505 ,  C07K14/415 ,  C07K16/18 ,  C07K16/22 ,  C07K16/241 ,  C07K16/2866 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/52 ,  C07K2317/522 ,  C07K2317/55 ,  C07K2317/569 ,  C07K2317/622 ,  C07K2319/00

Abstract: The invention provides a dual-specific ligand comprising a first and second single variable domain, each having binding specificity for a antigenic target. The invention also provides for a single variable domain monomer ligand that specifically binds to an antigenic target.

Abstract translation: 本发明提供了双特异性配体，其包含第一和第二单可变结构域，每一结构域对抗原靶具有结合特异性。 本发明还提供了与抗原靶特异性结合的单个可变域单体配体。

公开(公告)号：US20070003549A1

公开(公告)日：2007-01-04

申请号：US11331415

申请日：2006-01-11

Applicant: Olga Ignatovich ,  Steve Holmes ,  Roland Beckmann ,  Rudolf de Wildt

Inventor： Olga Ignatovich ,  Steve Holmes ,  Roland Beckmann ,  Rudolf de Wildt

IPC: A61K39/395 ,  C07K16/22

CPC classification number: C07K16/22 ,  A61K47/6845 ,  A61K47/6879 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/241 ,  C07K16/2863 ,  C07K16/40 ,  C07K2317/31 ,  C07K2317/55 ,  C07K2317/569 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2319/00

Abstract: Disclosed are ligands that have binding specificity for vascular endothelial growth factor (VEGF), for epidermal growth factor receptor (EGFR), or for VEGF and EGFR. Also disclosed are methods of using these ligands. In particular, the use of these ligands for cancer therapy is described.

Abstract translation: 公开了对血管内皮生长因子（VEGF），表皮生长因子受体（EGFR）或VEGF和EGFR具有结合特异性的配体。 还公开了使用这些配体的方法。 特别地，描述了这些配体用于癌症治疗的用途。

公开(公告)号：US20130109846A1

公开(公告)日：2013-05-02

申请号：US13415914

申请日：2012-03-09

Applicant: Murray McKinnon ,  Steven G. Nadler ,  Suzanne J. Suchard ,  Brendan Classon ,  Steve Holmes ,  Olga Ignatovich ,  Christopher Plummer ,  Steve Grant

Inventor： Murray McKinnon ,  Steven G. Nadler ,  Suzanne J. Suchard ,  Brendan Classon ,  Steve Holmes ,  Olga Ignatovich ,  Christopher Plummer ,  Steve Grant

IPC: C07K16/28

CPC classification number: C07K16/2818 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/2896 ,  C07K2317/31 ,  C07K2317/569 ,  C07K2317/73

Abstract: Disclosed are domain antibodies that monovalently bind CD28. Domain antibodies that are monovalent for binding of CD28 can inhibit CD28 activity. In one aspect, a domain antibody consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of CD28, in an aspect, without substantially agonizing CD28 activity. In another aspect, the domain antibody is a human domain antibody. The disclosure further encompasses methods of antagonizing CD80 and/or CD86 interactions with CD28 in an individual and methods of treating diseases or disorders involving CD80 and/or CD86 interactions with CD28, the methods involving administering a domain antibody to the individual.

公开(公告)号：US20100028354A1

公开(公告)日：2010-02-04

申请号：US12505166

申请日：2009-07-17

Applicant: Murray McKinnon ,  Steven G. Nadler ,  Suzanne J. Suchard ,  Brendan Classon ,  Steve Holmes ,  Olga Ignatovich ,  Christopher Plummer ,  Steve Grant

Inventor： Murray McKinnon ,  Steven G. Nadler ,  Suzanne J. Suchard ,  Brendan Classon ,  Steve Holmes ,  Olga Ignatovich ,  Christopher Plummer ,  Steve Grant

IPC: A61K39/395 ,  C07K16/00 ,  A61P37/00

CPC classification number: C07K16/2818 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/2896 ,  C07K2317/31 ,  C07K2317/569 ,  C07K2317/73

Abstract: Disclosed are domain antibodies that monovalently bind CD28. Domain antibodies that are monovalent for binding of CD28 can inhibit CD28 activity. In one aspect, a domain antibody consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of CD28, in an aspect, without substantially agonizing CD28 activity. In another aspect, the domain antibody is a human domain antibody. The disclosure further encompasses methods of antagonizing CD80 and/or CD86 interactions with CD28 in an individual and methods of treating diseases or disorders involving CD80 and/or CD86 interactions with CD28, the methods involving administering a domain antibody to the individual.

Abstract translation: 公开了单价结合CD28的结构域抗体。 对CD28结合而言是单价的域抗体可抑制CD28活性。 在一个方面，结构域抗体由一个方面组成或包含单个免疫球蛋白可变区，其特异性结合并拮抗CD28的活性，一方面，没有实质上激动的CD28活性。 另一方面，结构域抗体是人结构域抗体。 本公开还包括在个体中拮抗CD80和/或CD86相互作用的方法以及涉及与CD28相互作用的CD80和/或CD86相互作用的疾病或病症的方法，所述方法涉及对个体施用结构域抗体。

公开(公告)号：US20050271663A1

公开(公告)日：2005-12-08

申请号：US10925366

申请日：2004-08-24

Applicant: Olga Ignatovich ,  Rudolf de Wildt ,  Benjamin Woolven ,  Steven Grant ,  Philip Jones ,  Amrik Basran ,  Neil Brewis

Inventor： Olga Ignatovich ,  Rudolf de Wildt ,  Benjamin Woolven ,  Steven Grant ,  Philip Jones ,  Amrik Basran ,  Neil Brewis

IPC: A61K39/395 ,  A61K47/48 ,  A61K49/00 ,  C07H21/04 ,  C07K16/00 ,  C07K16/18 ,  C07K16/22 ,  C07K16/24 ,  C07K16/40

CPC classification number: C07K16/468 ,  A61K47/6879 ,  C07K16/005 ,  C07K16/18 ,  C07K16/22 ,  C07K16/241 ,  C07K16/30 ,  C07K16/40 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2319/00

Abstract: The invention relates to compositions and methods for treating inflammatory disorders. More specifically, the invention relates to antibody compositions and their use in the treatment of inflammatory disorders.

Abstract translation: 本发明涉及用于治疗炎症性疾病的组合物和方法。 更具体地，本发明涉及抗体组合物及其在治疗炎症性疾病中的用途。

公开(公告)号：US08168759B2

公开(公告)日：2012-05-01

申请号：US12505166

申请日：2009-07-17

Applicant: Murray McKinnon ,  Steven G. Nadler ,  Suzanne J. Suchard ,  Brendan Classon ,  Steve Holmes ,  Olga Ignatovich ,  Christopher Plummer ,  Steve Grant

Inventor： Murray McKinnon ,  Steven G. Nadler ,  Suzanne J. Suchard ,  Brendan Classon ,  Steve Holmes ,  Olga Ignatovich ,  Christopher Plummer ,  Steve Grant

IPC: C07K16/00 ,  A61K39/395

CPC classification number: C07K16/2818 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/2896 ,  C07K2317/31 ,  C07K2317/569 ,  C07K2317/73

Abstract: Disclosed are domain antibodies that monovalently bind CD28. Domain antibodies that are monovalent for binding of CD28 can inhibit CD28 activity. In one aspect, a domain antibody consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of CD28, in an aspect, without substantially agonizing CD28 activity. In another aspect, the domain antibody is a human domain antibody. The disclosure further encompasses methods of antagonizing CD80 and/or CD86 interactions with CD28 in an individual and methods of treating diseases or disorders involving CD80 and/or CD86 interactions with CD28, the methods involving administering a domain antibody to the individual.

Abstract translation: 公开了单价结合CD28的结构域抗体。 对CD28结合而言是单价的域抗体可抑制CD28活性。 在一个方面，结构域抗体由一个方面组成或包含单个免疫球蛋白可变区，其特异性结合并拮抗CD28的活性，一方面，没有实质上激动的CD28活性。 另一方面，结构域抗体是人结构域抗体。 本公开还包括在个体中拮抗CD80和/或CD86相互作用的方法以及涉及与CD28相互作用的CD80和/或CD86相互作用的疾病或病症的方法，所述方法涉及对个体施用结构域抗体。

公开(公告)号：US20080241166A1

公开(公告)日：2008-10-02

申请号：US12006933

申请日：2008-01-07

Applicant: Ian M. Tomlinson ,  Gregory P. Winter ,  Olga Ignatovich ,  Philip C. Jones ,  Lucy J. Holt

Inventor： Ian M. Tomlinson ,  Gregory P. Winter ,  Olga Ignatovich ,  Philip C. Jones ,  Lucy J. Holt

IPC: A61K39/395 ,  C07K16/00 ,  C07H21/00 ,  C12N15/63 ,  C12N5/00 ,  A61P35/00

CPC classification number: C07K16/2878 ,  A61K47/60 ,  A61K47/6845 ,  A61K47/6849 ,  A61K47/6871 ,  A61K47/6879 ,  A61K2039/505 ,  C07K16/005 ,  C07K16/18 ,  C07K16/241 ,  C07K16/40 ,  C07K16/468 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/569 ,  C07K2317/622 ,  C07K2319/00

Abstract: The invention relates to ligands, such as immunoglobulin single variable domains, that have binding specificity for a receptor. Preferably the receptor is a cell surface receptor and/or the ligand inhibits the activity of the receptor.

Abstract translation: 本发明涉及对受体具有结合特异性的配体，例如免疫球蛋白单可变结构域。 优选地，受体是细胞表面受体和/或配体抑制受体的活性。

公开(公告)号：US20060083747A1

公开(公告)日：2006-04-20

申请号：US11166496

申请日：2005-06-24

Applicant: Gregory Winter ,  Ian Tomlinson ,  Olga Ignatovich ,  Neil Brewis

Inventor： Gregory Winter ,  Ian Tomlinson ,  Olga Ignatovich ,  Neil Brewis

IPC: A61K39/395 ,  C07H21/04 ,  C12P21/06 ,  C12N5/06 ,  C07K16/46

CPC classification number: C07K16/00 ,  A61K2039/505 ,  C07K16/241 ,  C07K16/40 ,  C07K2317/52 ,  C07K2317/569 ,  C07K2317/94 ,  C07K2319/00

Abstract: The present invention relates to a simple method for generating antibody-based structures suitable for in vivo use. In particular, the invention relates to a method for the generation of antibody-based structures suitable for in vivo use comprising the steps of: (a) selecting an antibody single variable domain having an epitope binding specificity; and (b) attaching the single domain of step (a) to an effector group. Uses of molecules generated using the method of the Invention are also described.

Abstract translation: 本发明涉及一种生成适用于体内使用的基于抗体的结构的简单方法。 特别地，本发明涉及一种生成适合于体内应用的基于抗体的结构的方法，包括以下步骤：（a）选择具有表位结合特异性的抗体单可变结构域; 和（b）将步骤（a）的单一结构域连接到效应子组。 还描述了使用本发明的方法生成的分子的用途。

公开(公告)号：US20120201814A1

公开(公告)日：2012-08-09

申请号：US13416033

申请日：2012-03-09

Applicant: Murray McKinnon ,  Steven G. Nadler ,  Suzanne J. Suchard ,  Brendan Classon ,  Steve Holmes ,  Olga Ignatovich ,  Christopher Plummer ,  Steve Grant

Inventor： Murray McKinnon ,  Steven G. Nadler ,  Suzanne J. Suchard ,  Brendan Classon ,  Steve Holmes ,  Olga Ignatovich ,  Christopher Plummer ,  Steve Grant

IPC: A61K39/395 ,  A61P29/00 ,  A61P37/02 ,  A61P37/00 ,  A61P37/06

CPC classification number: C07K16/2818 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/2896 ,  C07K2317/31 ,  C07K2317/569 ,  C07K2317/73

Abstract: Disclosed are domain antibodies that monovalently bind CD28. Domain antibodies that are monovalent for binding of CD28 can inhibit CD28 activity. In one aspect, a domain antibody consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of CD28, in an aspect, without substantially agonizing CD28 activity. In another aspect, the domain antibody is a human domain antibody. The disclosure further encompasses methods of antagonizing CD80 and/or CD86 interactions with CD28 in an individual and methods of treating diseases or disorders involving CD80 and/or CD86 interactions with CD28, the methods involving administering a domain antibody to the individual.

Abstract translation: 公开了单价结合CD28的结构域抗体。 对CD28结合而言是单价的域抗体可抑制CD28活性。 在一个方面，结构域抗体由一个方面组成或包含单个免疫球蛋白可变区，其特异性结合并拮抗CD28的活性，一方面，没有实质上激动的CD28活性。 另一方面，结构域抗体是人结构域抗体。 本公开还包括在个体中拮抗CD80和/或CD86相互作用的方法以及涉及与CD28相互作用的CD80和/或CD86相互作用的疾病或病症的方法，所述方法涉及对个体施用结构域抗体。

公开(公告)号：US20110223168A1

公开(公告)日：2011-09-15

申请号：US13111516

申请日：2011-05-19

Applicant: Greg Winter ,  Ian Tomlinson ,  Olga Ignatovich ,  Lucy Holt ,  Elena De Angelis

Inventor： Greg Winter ,  Ian Tomlinson ,  Olga Ignatovich ,  Lucy Holt ,  Elena De Angelis

IPC: A61K39/395 ,  C07K16/44 ,  A61P11/06 ,  A61P37/08

CPC classification number: C07K16/18 ,  A61K47/60 ,  A61K2039/505 ,  C07K16/241 ,  C07K16/2866 ,  C07K16/2878 ,  C07K16/40 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/569 ,  C07K2317/622 ,  C07K2317/92 ,  C12N2799/021

Abstract: The invention provides a dual-specific ligand comprising a first immunoglobulin variable domain having a first binding specificity and a complementary or non-complementary immunoglobulin variable domain having a second binding specificity.

Abstract translation: 本发明提供了包含具有第一结合特异性的第一免疫球蛋白可变结构域和具有第二结合特异性的互补或非互补免疫球蛋白可变结构域的双重特异性配体。